In this article, some highlights on human epidermal growth factor 2 (HER2)-positive breast cancer presented during SABCS 2024 are discussed. In the early setting, several studies investigated neoadjuvant chemotherapy de-escalation strategies. Furthermore, the role of margetuximab in early breast cancer (EBC) was investigated in the phase II MARGOT trial. In the metastatic setting, the addition of palbociclib to endocrine and anti-HER2 therapy was evaluated in the PATINA trial including patients with hormone receptor (HR)-positive HER2-positive metastatic breast cancer (MBC). Finally, the final results of the PHILA trial were presented.
